Scopolamine Therapy Guidelines

Introduction to Scopolamine Therapy

• The National Comprehensive Cancer Network recommends scopolamine for secretion management in palliative care at a dose of 0.4 mg subcutaneously every 4 hours as needed 1
• The National Comprehensive Cancer Network suggests considering scopolamine in patients with persistent grade 2-4 diarrhea at 0.4 mg subcutaneously every 4 hours as needed 1
• Intensive Care Medicine does not routinely recommend scopolamine for prevention of upper airway secretions pre-extubation in palliative care 2

Administration and Dosage

• For secretion management in palliative care, scopolamine can be administered subcutaneously at a dose of 0.4 mg every 4 hours as needed, according to the National Comprehensive Cancer Network 1
• The NCCN palliative care guidelines recommend a subcutaneous dosage of 0.4 mg of scopolamine every 4 hours as needed for patients requiring secretion management 1
• Dose reduction or alternative medications, such as glycopyrrolate, should be considered for patients at higher risk of adverse effects, particularly delirium and toxic psychosis, including elderly and pediatric populations, as suggested by the NCCN guidelines 1, 3

Contraindications and Precautions

• Scopolamine is contraindicated in pregnancy due to its ability to cross the placenta 1
• Scopolamine is contraindicated for patients with recurrent obstructive pneumonia and continuous sputum production, as it can worsen their condition by drying secretions and potentially causing delirium, according to the National Comprehensive Cancer Network 3
• The American Thoracic Society and European Respiratory Society recommend managing recurrent obstructive pneumonia with secretion clearance methods, such as chest physiotherapy, adequate hydration, postural drainage, and mucolytics, and treating underlying pneumonia with appropriate antibiotics based on likely pathogens and local resistance patterns 4, 5

Adverse Effects

• Scopolamine can cause significant anticholinergic side effects, including:

• The National Comprehensive Cancer Network warns that adding scopolamine to other medications with anticholinergic properties could lead to cumulative toxicity, especially in elderly patients 3
• Elderly and pediatric patients are more susceptible to delirium and toxic psychosis when using scopolamine, and its use should be avoided in these populations if possible 1

Special Considerations

• Transdermal scopolamine patches have a delayed onset of approximately 12 hours, making them inappropriate for acute management of secretions 3
• The American Thoracic Society recommends considering LABA/LAMA combinations for patients with obstructive components to optimize bronchodilation 6